Samsung is collaborating with Massachusetts General Hospital to study the effects of GLP-1 medications, such as Ozempic, on muscle loss. The study will utilize the Galaxy Watch 8 to monitor body composition, activity levels, and heart rate in individuals starting GLP-1 treatment. Researchers aim to determine if continuous biometric data from wearables can help manage and mitigate muscle mass reduction, a known side effect of these popular drugs. AI
IMPACT This study could lead to new health monitoring features in wearables, helping users manage side effects of popular weight-loss drugs.
RANK_REASON Samsung is using its existing wearable product to study a health phenomenon, not releasing a new AI model or core AI research.
- Chung-Ang University Gwangmyeong Hospital
- Dr. Melissa Putman
- Galaxy Watch 8
- GLP-1
- Massachusetts General Hospital
- Ozempic
- Samsung
- Stanford University
AI-generated summary · Google Gemini · from 2 sources. How we write summaries →
